Daily Roundup | Tecentriq Approved After dMMR Colon Cancer Surgery & Zenbexus Topline: Median PFS 42 vs 20 Months

<p>Thursday, October 8 edition, published after midnight Pacific.</p><p><br></p><p>FDA approves Roche&#39;s Tecentriq (atezolizumab) with chemotherapy after stage III dMMR colon cancer surgery: fewer recurrence-or-death events, more frequent grade 3–4 adverse events. Bristol Myers Squibb reports a topline median progression-free survival of 42 vs 20 months for Zenbexus (iberdomide) in multiple myeloma; the result is not peer-reviewed, reports no overall survival result, and whether it verifies clinical benefit is the FDA&#39;s call. argenx stops its Phase 3 UNITY study of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in Sjögren&#39;s disease and says FB102 met its Phase 2 celiac primary endpoint. Plus Viatris&#39;s pending $1.65 billion Pacira deal (EXPAREL, ZILRETTA), PhRMA&#39;s GLOBE lawsuit, GenSight&#39;s GS030 retinitis pigmentosa study and Valneva&#39;s UK IXCHIQ revocation.</p><p><br></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>